CSL Behring Invests €610 Million to Expand Marburg Plasma Plant, Adding 100 Jobs
CSL Behring will invest €610 million to expand its Marburg plant, adding at least 100 jobs and safeguarding 300 existing positions through 2030.
Australian biopharma giant CSL Behring will spend 610 million euros to expand its Marburg plant through 2030, the largest single investment in the site’s 120-year history.
- Two new filling lines with eight lyophilizers and a dedicated bulk facility for fibrinogen will come online in 2029.
- The expansion offsets the ongoing closure of the site’s research division, which eliminates 500 positions at the Innovation subsidiary.
CSL Behring, the Australian-listed plasma-therapy leader, announced the capital commitment Thursday at its Marburg campus, the company’s largest manufacturing hub globally with 2,800 staff producing roughly 18 million finished packs in the fiscal year ended June 30, 2026, FAZ reported. The funds target plasma-derived therapies for rare, chronic, and serious conditions, serving more than 300,000 patients across Europe and a growing global cohort.
“The investment of 610 million euros stands for the long-term commitment of the company to Marburg, to Germany and above all to the patients,” said Annegret Wittich-Hoeffer for the Germany, Austria, and Switzerland region. “Securing the next generation of production depends on maintaining a competitive, innovation-friendly environment.”
Hesse Economics Kaweh Mansoori (SPD) called the decision a strengthening of the state’s industrial core that safeguards 300 existing jobs and adds at least 100 new positions, according to a company spokesman cited by Deutsche Apotheker Zeitung.

Fibrinogen facility addresses critical supply gap
A dedicated bulk plant for fibrinogen anchors the expansion. The European Medicines Agency classifies fibrinogen as a critical medicine — indispensable for population supply — used to treat life-threatening bleeding in congenital or acquired fibrinogen deficiency following surgery, childbirth, or severe trauma. CSL is the sole manufacturer of the active substance in Germany, and the company says demand for larger volumes exists.
Two new aseptic filling lines equipped with eight freeze-dryers will raise capacity for the broader plasma portfolio, including immunoglobulins and coagulation factors. Commissioning is slated for 2029. Additional spending on automation and digital process control aims to harden long-term operational resilience and retain manufacturing know-how in Germany, the company said.
Research exit proceeds in parallel
The capital infusion coincides with the phased shutdown of CSL’s research operations at Marburg. The Innovation subsidiary, employing roughly 500 people, is winding down, a decision communicated last year. Site director Niklas Schier acknowledged the tension: “History in Marburg is a good basis, but no guarantee for new investments. It takes framework conditions like locally trained specialists, proximity to the university, and good infrastructure, but also competitive production costs.”
TransMit GmbH, the technology-transfer office for the three central-Hesse universities, has reported inquiries from Innovation staff about operating a start-up center on the campus. Marburg Thomas Spies (SPD) said the city will support a “start-up hub” with two million euros. Currently, about four-fifths of the city’s trade tax revenue comes from the pharmaceutical sector.
Strategic context: second major Hesse pharma bet in weeks
CSL’s move follows Sanofi’s recent large-scale production investment in Frankfurt, marking the second global pharma company in weeks to commit significant capital to Hesse manufacturing. Marburg’s lineage traces to 1904, when Nobel laureate Emil von Behring founded a factory with Farbwerke Hoechst. BioNTech currently fills vaccines at the site but will cease that activity by 2028.
CSL operates four manufacturing sites worldwide with 29,000 employees total. Marburg supplies more than 100 countries from its German base.
CSL Behring traces its roots to Behringwerke, founded in 1904 in Marburg by Emil von Behring, winner of the first Nobel Prize in Medicine for serum therapy, and to the Commonwealth Serum Laboratories established in Australia in 1916.
The two legacies merged through acquisitions after 2004, adopting the CSL Behring name in 2007. The parent company, CSL Limited, is headquartered in Melbourne and employs more than 27,000 people across 30 countries, operating the world’s largest plasma collection network through CSL Plasma with over 270 centres.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.